Symbyax

Product manufactured by Eli Lilly And Company

Application Nr Approved Date Route Status External Links
NDA021520 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Symbyax ® Is Indicated For The Treatment Of: Acute Depressive Episodes In Bipolar I Disorder [See Clinical Studies ( 14.1 )] . Treatment Resistant Depression (Major Depressive Disorder In Patient Who Do Not Respond To 2 Separate Trials Of Different Antidepressants Of Adequate Dose And Duration In The Current Episode) [See Clinical Studies ( 14.2 )] . Symbyax ® Combines Olanzapine, An Atypical Antipsychotic And Fluoxetine, A Selective Serotonin Reuptake Inhibitor, Indicated For Treatment Of: Acute Depressive Episodes Associated With Bipolar I Disorder ( 1 ) Treatment Resistant Depression ( 1 )

All Formulated Excipients (0 Total)

None

Active Ingredients ( 2 Total)

Comments